Aligos Therapeutics, Inc. (ALGS) — Financial statements
Income statement, balance sheet, and cash flow for Aligos Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2↓44.6% | 4↓74.6% | 16↑11.7% | 14↑219.0% | 4 | |
| Cost of Revenue | 0.93 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 1↓68.2% | 4↓74.6% | 16↑11.7% | 14↑219.0% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 69↓1.2% | 70↓3.8% | 73↓14.1% | 85↓18.3% | 104 | |
| General & Administrative Expenses | 21↓9.3% | 23↓25.4% | 31↑15.9% | 26↓7.4% | 29 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 21↓9.3% | 23↓25.4% | 31↑15.9% | 26↓7.4% | 29 | |
| Other Expenses | -0.93 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 89↓4.1% | 93↓10.2% | 104↓7.0% | 111↓16.0% | 133 | |
| Total Costs & Expenses | 90↓3.1% | 93↓10.2% | 104↓7.0% | 111↓16.0% | 133 | |
| Operating Results | ||||||
| Operating Income | -88↑1.3% | -89↓1.2% | -88↑9.7% | -98↑24.0% | -128 | |
| Depreciation & Amortization | 0.93↓64.5% | 3↓14.6% | 3↓16.5% | 4↓2.7% | 4 | |
| EBITDA | -87↓0.6% | -87↓1.7% | -85↑9.4% | -94↑24.6% | -125 | |
| EBIT | -88↑1.3% | -89↓1.2% | -88↑9.7% | -98↑24.0% | -128 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑29.6% | 2↑34.4% | 1↓24.2% | 2↑1142.4% | 0.13 | |
| Interest Income | 2↑29.6% | 2↑34.4% | 1↓24.2% | 2↑1142.4% | 0.13 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 64↑253.6% | -42↓3456.9% | 1↓24.2% | 2↑1142.4% | 0.13 | |
| Income Before Tax | -24↑81.8% | -131↓50.6% | -87↑9.4% | -96↑25.2% | -128 | |
| Income Tax Expense | 0.31↓5.1% | 0.33↓58.4% | 0.80↑650.0% | 0.11↓25.9% | 0.14 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -24↑81.6% | -131↓49.6% | -88↑8.7% | -96↑25.2% | -128 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -24↑81.6% | -131↓49.6% | -88↑8.7% | -96↑25.2% | -128 | |
| Bottom-Line Net Income | -24↑81.6% | -131↓49.6% | -88↑8.7% | -96↑25.2% | -128 | |
| EPS (Basic) | -2.45↑88.3% | -20.94↓494.9% | -3.52↓56.4% | -2.25↑30.1% | -3.22 | |
| EPS (Diluted) | -2.45↑88.3% | -20.94↓494.9% | -3.52↓56.4% | -2.25↑30.1% | -3.22 | |
| Weighted Average Shares | 10↑57.8% | 6↓74.8% | 25↓41.7% | 43↑7.1% | 40 | |
| Weighted Average Diluted Shares | 10↑57.8% | 6↓74.8% | 25↓41.7% | 43↑7.1% | 40 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.